Two Phase III Trials Show Increase In PFS In Two Distinct Patient Populations
Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%
Two Conflicting Studies Presented at ASCO 2013, FDA Called Upon To Sort Through The Data
Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events
Votrient Trial Meets PFS Endpoint In Epithelial Ovarian Cancer
Afinitor Extends PFS In Women With EGFR-2 Positive Disease
Analysis Reveals CAIX Subgroup Responsive to Rencarex Therapy
Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III
CTEP-Approved Trials For the Month of June
FDA Approves Two Oral Drugs For Metastatic Melanoma
Trending Stories
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
- Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home
- How the 2024 elections can impact cancer policy
- NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials
- Less Radical podcast: The origins of modern surgery, radical mastectomy, and the first randomized trials in breast cancer
- Evaluation of cancer care in Ukraine shows good access to treatment despite wartime
Work remains to be done to ensure high-quality care